New hope for rare sinus cancer: combined therapy shows promise
NCT ID NCT07449949
First seen Apr 01, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This study tests a treatment plan for adults with a rare cancer of the nasal and sinus cavities called rhabdomyosarcoma. The plan involves chemotherapy and radiation before and after surgery. The goal is to see if this approach can shrink tumors and improve survival. The study will enroll 43 people who have not been treated before.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
EENT hospital of Fudan University
Shanghai, China, 200000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vincristine, Actinomycin D, Epirubicin, Cisplatin, Cyclophosphamide, and radiation therapy
What this could lead to
If successful, this could provide a standard treatment approach for a rare cancer that currently lacks established guidelines.
What could go wrong
This is a small, single-arm study with only 43 participants, so results may not apply to all patients. The treatment involves strong chemotherapy and radiation, which can cause significant side effects.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.